Vernalis plc
From Wikipedia, the free encyclopedia
| Public company | |
| Traded as | LSE: VER NASDAQ: VNLS |
| Industry | Biotechnology |
| Founded | 2003 |
| Headquarters | Winnersh, United Kingdom |
|
Key people
|
Ian Garland (CEO) Peter Fellner (Executive chairman) |
| Products | Frovatriptan, Apokyn |
|
Number of employees
|
200 |
| Website | vernalis.com |
Vernalis plc is a British based biotech company founded in 2003 by the merger of Vernalis Group with British Biotech in a deal valued at £90 million.[1] The merger allowed British Biotech to ditch its historic but tarnished name.[2]
The company has marketed two drug products; Frovatriptan,[3] to treat migraine, and Apokyn, an apomorphine-based drug for advanced Parkinson's disease.[4]
The company has a development pipeline focused on CNS disease and oncology, and collaborates with pharmaceutical companies including Novartis, Servier, ChemGenex and Serono. It is listed on the London Stock Exchange and is a constituent of the FTSE Fledgling Index.
References[edit]
- ^ "Vernalis agrees £91m merger plan with British Biotech". Advances in Life Science. ALS. 2003. Retrieved 3 July 2003.
- ^ "Fifth Report". Select Committee on Science and Technology. House of Commons. 1998. Retrieved 28 November 2007.
- ^ "Patient Information Sheet – Frovatriptan succinate (marketed as Frova)". Food and Drug Administration. July 2006. Archived from the original on 29 September 2007. Retrieved 28 November 2007.
- ^ "Apokyn". FDA. 2004. Retrieved 29 July 2004.[dead link]
External links[edit]
 |
This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it. |
